Sugammadex/Neostigmine and Liver Transplantation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-01-31

Study Completion Date

2019-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Cirrhotic patients undergoing liver transplantation are at very high risk of post operative complication such as post-operative residual curarization.

Rocuronium is a neuromuscular blocking agent that nowadays can be safely and rapidly antagonized with sugammadex.

No one study compared sugammadex versus neostigmine after rocuronium infusion during liver transplantation.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Role of Sugammadex and Neostigmine for Recovery From Rocuronium

NCT06432621

Anesthesia

ACTIVE_NOT_RECRUITING NA

Comparison of Rocuronium and Org 25969 With Cisatracurium and Neostigmine (19.4.310)(P05931)

NCT00451100

Anesthesia, General

COMPLETED PHASE3

Using Diaphragm Ultrasonography, Sugammadex Recovers Diaphragmatic Function More Effectively Than Neostigmine.

NCT06982092

Perioperative Diaphragmatic Function

COMPLETED PHASE1

Diaphragm Ultrasound to Evaluate the Antagonistic Effect of Sugammadex

NCT05028088

Diaphragm Ultrasonography Liver Dysfunction Sugammadex +1 more

UNKNOWN PHASE4

Comparison of Sugammadex With Neostigmine as Reversal Agents for Rocuronium at Reappearance of T2 (Study P06101)

NCT01050543

Neuromuscular Blockade

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

It is known that major abdominal surgery is associated with increased risk of morbidity and postoperative mortality. The complexity and the duration of the procedure as well as the failure to antagonize neuromuscular blocking agents at the end of surgical procedure are risk factors for postoperative complications.

Muscle relaxation plays an important role that is to facilitate intubation and to allow a better surgical condition. For this reason it is necessary to maintain, during the surgery, a deep neuromuscular block.

Deep block at the level of the adductor muscle of the thumb is obtained by measuring 1-2 responses during post-tetanic stimulation (the so-called Post-Tetanic Count or PTC).

The maintenance of a deep neuromuscular block requires further doses of neuromuscular blockers and, therefore, the need of long recovery times regardless of the drug used.

Pharmacodynamics and pharmacokinetics of neuromuscular blocking and reversals commonly used in clinical practice can undergo significant changes due to the presence of alterations in organ function such as hepatic and renal insufficiency. In these patients we see more frequent adverse events such as prolonged neuromuscular blockade and postoperative residual curarization.

In the literature it is considered suitable a recovery from neuromuscular block if the relationship between the fourth and first contraction during Train of Four (TOF) is greater than 0.9 (TOF-ratio\> 0.9). This may take a long time so the reversal of blocking agents at the end of the surgical procedure is the solution to reduce this waiting period. The importance of an adequate recovery from neuromuscular block at the end of anesthesia is related to avoid postoperative residual paralysis (PORC) and reducing the risk of postoperative respiratory complications potentially fatal.

Rocuronium is characterized by an increase in half-life and an increase in the recovery time of neuromuscular transmission (TOF ratio of 0.9) in cirrhotic patients compared to controls healthy people.

To prevent residual neuromuscular blockade and all the complications that it brings with it it could be resorted the use of anti-cholinesterase drugs (neostigmine) to antagonize indirectly the action of non-depolarizing neuromuscular blocking agents. Neostigmine works by increasing the availability of acetylcholine at the neuromuscular junction. The administration of neostigmine may however cause bronchospasm, abdominal pain, nausea, cardiac arrhythmias and can not be used if the neuromuscular blockade is deep. Recently the use of sugammadex, a new drug that can act as an antidote to a comparison of non-depolarizing muscle relaxants amino-steroidal (rocuronium, vecuronium) showed good clinical impact. This drug works by encapsulating the muscle relaxant molecule in the plasma with a high affinity and binding to the complex thus formed which is then eliminated by the kidney. Sugammadex is characterized by the absence of adverse effects at the recommended doses and may be administered at correct dosage, even at deep neuromuscular blockade.

Several studies have shown that the recovery from neuromuscular blockade induced by rocuronium is significantly faster after administration of sugammadex compared with neostigmine both when used in moderate block levels and deep.

In literature there are no data and studies that assessed the recovery time of neuromuscular transmission (TOF ratio\> 0.9) with the use of sugammadex verus neostigmine in patients undergoing liver transplantation after rocuronium infusion.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Postoperative Residual Curarization Liver Transplantation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

sugammadex

at the end of surgery administration of 2 mg/kg of sugammadex after the third T2 twitch at Train of Four (TOF) stimulation

Group Type ACTIVE_COMPARATOR

sugammadex

Intervention Type DRUG

neostigmine

at the end of surgery administration of 50 mcg/kg of neostigmine after the third T2 twitch at Train of Four (TOF) stimulation

Group Type ACTIVE_COMPARATOR

Neostigmine

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

sugammadex

Intervention Type DRUG

Neostigmine

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* American Society of Anesthesiology status (ASA) III
* Ability to give a written informed consent
* Liver transplantation

Exclusion Criteria

* Any allergy to medications involved in the study
* Any disease involving neuromuscular transmission
* Any therapy with toremifene, flucloxacillin or fusidic acid
* Renal disease with glomerular filtration rate less than 30 ml/min/1.73m2
* Hyperthermia maligna
* Anticonceptional therapy
* Pregnancy
* Core body temperature less than 35°C or skin temperature less than 32°C at the end of surgery

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No